

Buy-back of ordinary shares in BONESUPPORT HOLDING AB 15-18 June 2026 (week 25). The buy-back program is now completed and closed.

BONESUPPORT HOLDING AB (LEI CODE: 549300COLY053IGTLD63) ("BONESUPPORT") has during 15 June 2026 up to and including 18 June 2026 repurchased a total of 193,320 own ordinary shares (ISIN: SE0009858152) as part of the buy-back program initiated by the Board of Directors of BONESUPPORT™. The buy-back program is now completed and has been closed.

The repurchases formed part of the buy-back program of maximum 373,320 ordinary shares for a total amount of maximum SEK 100 million announced by BONESUPPORT on 8 June 2026 and which ran during the period 9 June 2026 until and including 18 June 2026. The buy-back program was carried out for the purpose of ensuring BONESUPPORT's obligations arising from the long-term share savings program LTI 2026 resolved by the Annual General Meeting on 12 May 2026. The repurchases were carried out in accordance with the Market Abuse Regulation (EU) 596 /2014 ("MAR") and the European Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation").

Ordinary shares in BONESUPPORT have been repurchased as follows:

Date	Aggregate daily volume (number of shares)	Weighted average price per day (SEK)	Total Daily Transaction Value (SEK)
15 June 2026	40,000	224.3862	8,975,449
16 June 2026	45,000	220.6155	9,927,696
17 June 2026	60,000	209.8594	12,591,565
18 June 2026	48,320	210.2516	10,159,356
Total during week 25, 2026	193,320	215.4669	41,654,067
Total accumulated during buyback program	373,320	221.9935	82,874,596

All repurchases have been carried out on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ) on behalf of BONESUPPORT. Following the above repurchases, BONESUPPORT's holding of treasury shares up to and including 18 June 2026 amounts to 373,320 ordinary shares and 905,155 Series C shares.

As of 18 June 2026, the total number of shares in BONESUPPORT, including treasury shares, is 66,764,350, of which 65,859,195 are ordinary shares and 905,155 are Series C shares. The total number of outstanding shares in BONESUPPORT, excluding treasury shares, is 65,485,875, all of which are ordinary shares.

Complete information about the transactions carried out in accordance with Article 5.3 of MAR and Article 2.3 of the Safe Harbour Regulation is attached to this press release.

For more information contact:

BONESUPPORT Holding AB
Torbjörn Sköld, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to 1,175 msek in 2025. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

ENG Supplement Share Buyback Week 25 2026
Buy-back of ordinary shares in BONESUPPORT HOLDING AB 15-18 June 2026 (week 25). The buy-back program is now completed and closed.